**SLC25A22 Is a Novel Gene for Migrating Partial Seizures in Infancy**

Annapurna Poduri, MD, MPH,1,2 Erin L. Heinzen, PhD,3 Vida Chitsazzadeh, BS,4
Francesco Massimo Lasorsa, PhD,5,6 P. Christina Elhosary, BS,1
Christopher M. LaCoursiere, BS,1 Emilie Martin, BS,1
Christopher J. Yuskaitis, MD, PhD,1 Robert Sean Hill, PhD,7
Kutay Deniz Atabay, MS,7 Brenda Barry, MS,7 Jennifer N. Partlow, MS,7
Fahad A. Bashiri, MD,8 Radwan M. Zeidan, MD,9 Salah A. Elmalik, MD,10
Mohammad M. U. Kabiraj, MBBS, MPhil, PhD,11 Sanjeev Kothare, MBBS,1,2
Tommy Stödberg, MD,12 Amy McTague,13,14 Manju A. Kurian,13,14
Ingrid E. Scheffer, MBBS, PhD, FRACP,15 A. James Barkovich, MD,16
Ferdinando Palmieri, PhD,5,6,17 Mustafa A. Salih, MD, Dr Med Sci,8 and
Christopher A. Walsh, MD, PhD2,7

**Objective:** To identify a genetic cause for migrating partial seizures in infancy (MPSI).

**Methods:** We characterized a consanguineous pedigree with MPSI and obtained DNA from affected and unaffected family members. We analyzed single nucleotide polymorphism 500K data to identify regions with evidence of linkage. We performed whole exome sequencing and analyzed homozygous variants in regions of linkage to identify a candidate gene and performed functional studies of the candidate gene SLC25A22.

**Results:** In a consanguineous pedigree with 2 individuals with MPSI, we identified 2 regions of linkage, chromosome 4p16.1-p16.3 and chromosome 11p15.4-pter. Using whole exome sequencing, we identified 8 novel homozygous variants in genes in these regions. Only 1 variant, SLC25A22 c.G328C, results in a change of a highly conserved amino acid (p.G110R) and was not present in control samples. SLC25A22 encodes a glutamate transporter with strong expression in the developing brain. We show that the specific G110R mutation, located in a transmembrane domain of the protein, disrupts mitochondrial glutamate transport.

**Interpretation:** We have shown that MPSI can be inherited and have identified a novel homozygous mutation in SLC25A22 in the affected individuals. Our data strongly suggest that SLC25A22 is responsible for MPSI, a severe condition with few known etiologies. We have demonstrated that a combination of linkage analysis and whole exome...
sequencing can be used for disease gene discovery. Finally, as SLC25A22 had been implicated in the distinct syndrome of neonatal epilepsy with suppression bursts on electroencephalogram, we have expanded the phenotypic spectrum associated with SLC25A22.

**Subjects and Methods**

Subjects with MPSI and their families were ascertained from Saudi Arabia, the United States, Australia, Sweden, and New Zealand. Detailed history, neurological examination, EEG, and neuroimaging were performed clinically. Informed consent was obtained in accordance with the institutional review boards (IRBs) of Boston Children’s Hospital and Beth Israel Deaconess Medical Center in Boston as well as the local IRBs of the referring institutions. Work on deidentified samples at the Duke Center for Human Genome Variation (CHGV) was approved by the IRB of Duke University School of Medicine. Clinical data were reviewed by 2 neurologists (M.A.S., A.P.); neuroimaging was reviewed by 3 neurologists and 1 neuroradiologist (M.A.S., A.P., C.A.W., A.J.B.).

Blood samples were collected from consenting subjects, including affected individuals and their parents and unaffected siblings. DNA was extracted using standard methods from peripheral blood lymphocytes. DNA was digested, amplified, and hybridized to an Affymetrix (Santa Clara, CA) 500K single nucleotide polymorphism (SNP) array at the Broad Institute (Cambridge, MA).

Assuming an autosomal recessive mode of inheritance with 100% penetrance and a susceptibility allele frequency of 0.1%, we analyzed SNP data from the pedigree described in this report to evaluate for evidence of genetic linkage using Allegro (Boxborough, MA) software. Copy number was assessed using dChip software (Affymetrix).

DNA from 1 affected individual (EP-201) was used for whole exome sequencing at the Duke CHGV using the Illumina (San Diego, CA) Genome Analyzer IIX massively parallel sequencing system. Alignment to the human genome (reference build hg18) was conducted using Burrows-Wheeler Aligner version 0.5.5.12 SAMtools version 0.1.12 was used to make consensus and variant calls. Annotation, filtering for quality, filtering to remove potential variants present in dbSNP129 or in 220 individuals from a group nonenriched for neuropsychiatric phenotypes, and prediction of functional effects of potential mutations were performed using Sequent Variant Analyzer (http://www.svaproject.org). After an initial list of variants was generated in this manner, we limited the list of candidate mutations to include only those variants present in the regions for which there was evidence of linkage and only those variants in those regions that were homozygous or that represented possible compound heterozygous mutations. We further eliminated variants present in dbSNP130 after inspection of each variant prior to elimination to ensure that there was evidence that the variant was a true polymorphism. We prioritized variants that were predicted to produce a premature truncation, nonsynonymous coding change, or disruption of a canonical splice site. Further analysis of functional homozygous variants in the regions of linkage was performed using the University of California, Santa Cruz Genome Browser (www.genome.ucsc.edu) and Sorting Intolerant From Tolerant (SIFT) mutation prediction software (http://blocks.fhcrc.org/sift/SIFT.html).

Primers were designed using Primer3 software13 to confirm potentially pathogenic mutations by Sanger sequencing in EP-201 and establish the genotype in the other family members. Sanger sequencing and Sequenom (San Diego, CA) genotyping were used to evaluate for the presence of potential mutations in 3 additional families and 14 sporadic cases of MPSI, 144 Middle Eastern unaffected individuals, and 576 neurologically normal Caucasian control individuals from the National Institute of Neurological Disorders and Stroke (NINDS) through the Coriell Institute for Medical Research (Camden, NJ).

We overexpressed wild-type (WT) SLC25A22 using a commercially available plasmid (Origene, Rockville, MD) tagged with green fluorescent protein (GFP) in COS-7 cells in culture to determine the pattern of cellular localization. We
then used site-directed mutagenesis to create a mutant construct containing the c.G328C variant using the QuikChange II mutagenesis system (Stratagene Cloning Systems, La Jolla, CA). We confirmed the WT and mutant sequences with polymerase chain reaction (PCR). We overexpressed the GFP-tagged mutant construct into COS-7 cells. Transfections were performed using Fugene 6 transfection reagents (Roche, Indianapolis, IN). We stained for GFP as well as a nuclear counterstain, 4',6-diamidino-2-phenylindole, and a mitochondrial marker, MitoTracker Red CMXRos.

To conduct functional studies of WT versus G110R SLC25A22 using a bacterial system, plasmids were constructed containing the coding sequence for WT SLC25A22 amplified by PCR from human brain cDNA. The Gly110Arg mutation was introduced into the WT SLC25A22 cDNA by overlap-extension PCR. Constructs were transformed into Escherichia coli TOP10 cells. Overproduction of WT and G110R mutant SLC25A22 as inclusion bodies in the cytosol of E. coli was accomplished according to standard methods. The same amount of each recombinant protein was used for in vitro reconstitution of SLC25A22 into liposomes. Then the [14C]glutamate/glutamate exchange in proteoliposomes reconstituted with the recombinant WT or the G110R mutant SLC25A22 (also known as glutamate carrier 1, or GC114) was measured after 1-minute incubation (in the initial linear range of uptake to measure the specific activity) and after 60-minute incubation (when radioactive uptake by proteoliposomes had approached equilibrium), as described previously.15–18 Full details are provided in the Supplementary Methods section.

Results

MPSI in a Consanguineous Pedigree

The pedigree shown in Figure 1 depicts 2 affected children (EP-201 and EP-202) with MPSI, 1 male and 1 female. Their parents were first cousins from Saudi Arabia with Sudanese ancestry; there were 2 unaffected brothers. DNA was obtained from these 6 individuals.

The clinical features of both affected siblings are summarized in Table 1. EP-201, the affected boy, presented with seizures at 1 week of age. The initial seizures appeared as hemiconvulsions on the right side of the body that migrated to the left side within 3 days; accompanying the convulsive activity, there was flushing of the face, staring, and eventually bilateral eyelid blinking. The general examination was unremarkable, and the neurological examination revealed hypotonia and brisk deep tendon reflexes (DTRs). EEG performed at 1 month of age showed a delta brush pattern in the left midtemporal region (T7), positive spikes in the right midtemporal region (T8), and high-voltage focal spikes in the right and left frontal regions. Magnetic resonance imaging (MRI), also performed at 1 month of age, was normal. An extensive neurometabolic screen included evaluation of serum ammonia, lactate, and venous blood gas, and analysis of blood by tandem mass spectrometry as well as evaluation of urine for sulfocysteine and xanthine and by gas chromatography and mass spectrometry. The results were all normal. Brainstem auditory evoked responses (BAERs), visual evoked potentials (VEPs), and electroretinogram (ERG) were all normal. Seizures were only

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Seizure Types</th>
<th>Age of Seizure Onset, wk</th>
<th>Examination</th>
<th>Development</th>
<th>Age of Death, mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP-201</td>
<td>Male</td>
<td>Hemiconvulsive with color change and staring</td>
<td>1</td>
<td>Hypotonic brisk DTRs</td>
<td>Delay, arrest</td>
<td>14</td>
</tr>
<tr>
<td>EP-202</td>
<td>Female</td>
<td>Hemiconvulsive</td>
<td>2</td>
<td>Hypotonic brisk DTRs</td>
<td>Delay, arrest</td>
<td>47</td>
</tr>
</tbody>
</table>

DTR = deep tendon reflex.

December 2013 875
partially responsive to carbamazepine and diazepam treatment. There was delay and subsequent arrest of development, and the child died at 14 months of age.

EP-202, the affected girl, presented with seizures at 2 weeks of age. The seizures were described as bilateral and hemiconic convulsions of the right side more than the left, accompanied by bilateral eyelid fluttering. The general examination was unremarkable, and the neurological examination revealed hypotonia and brisk DTRs. EEG performed at 6 months of age showed independent focal spikes in a multifocal distribution and partial seizures of multifocal origin. Brain MRI, performed at 3 months of age and again at 2 years of age, revealed a delayed myelination pattern and diffuse thinning of the corpus callosum.

This child, in addition to the evaluation undertaken for her brother, had evaluation of creatine kinase, very long chain fatty acids, high-resolution karyotype, and a muscle biopsy (histology and histochemistry to evaluate for mitochondrial dysfunction), all of which were normal. BAERs and ERG were normal, but VEPs suggested bilateral optic pathway involvement. Seizures were refractory to treatment with phenobarbital, diazepam, pyridoxine, topiramate, and carbamazepine. Development was delayed and subsequently arrested. She died at 47 months of age.

**Linkage Analysis and Copy Number Results**

We obtained Affymetrix 500K SNP data from individuals EP-201, EP-202, EP-203, EP-204, and EP-206. In our genome-wide analysis of these data, we found only 1 region spanning a genetic distance of >2cM with apparent identity by descent at chromosome 4p16.1-p16.3, flanked by SNPs rs10001263 and rs6826371 (base pair position chr4:74,508-10,760,828, hg18), in which SNPs were homozygous in the unaffected individuals but heterozygous in the affected individuals. Linkage analysis of this 9.6Mb region of homozygosity resulted in a logarithm of odds (LOD) score of 2.06, the maximum expected LOD score for a pedigree of this size and structure. A smaller region of 3.2Mb at chromosome 11p15.4-pter, from the telomere to SNP_A-1791882 (base pair position chr11:1-3,164,265, hg18), was also associated with a maximum LOD score of 2.06. A representation of the SNP genotypes, a plot of the LOD scores, and a display of the genes in the regions are shown in Figure 2. Together these regions contained at least 204 annotated genes. Copy number evaluation confirmed that both EP-201 and EP-202 were homozygous for the observed SNVs, and the parents and siblings were all heterozygous.

**Further Analysis of Variants Identified by Whole Exome Sequencing**

Of the 8 homozygous SNVs in the regions with evidence of linkage in our MPSI pedigree, there was strong conservation across species and predicted disruption of the protein only for GPR78 and SLC25A22. Sanger sequencing confirmed that both EP-201 and EP-202 were homozygous for the observed SNVs, and the parents and siblings were all heterozygous.

GPR78 is a poorly characterized orphan G-protein coupled receptor. Sanger sequencing of 96 controls from the Middle East unrelated to the EP-200 family for the observed SNV in GPR78 revealed 2 of 96 individuals to be heterozygous for the R>Q variant. Based on this observation, if the homozygous p.R311Q variant were pathogenic, we would predict that MPSI caused by this mutation alone would be present in at least ~1 of 10,000 Middle Eastern children (1/4 × 1/48 × 1/48). As MPSI appears to be far more rare than 1 in 10,000, we concluded that this variant was an as yet unannotated polymorphism without pathogenic significance.

Using Sequenom genotyping, we evaluated the same 96 plus an additional 48 Middle Eastern controls as well as an additional 576 neurologically normal controls from NINDS for the SLC25A22 c.G328C, p.G110R variant. No control individuals possess this variant. We also evaluated SNP data from the National...
FIGURE 2: The single nucleotide polymorphism (SNP) genotype, plot of the logarithm of odds (LOD) score, and schematic display of the genes in the regions are shown for the 2 regions with maximal LOD score in the EP-200 family. (A) The region at chromosome 4p16.1-p16.3. (B) The region at chromosome 11p15.4-pter. SLC25A22 is circled in red. The SNPs displayed as red and blue represent homozygous genotypes, whereas those shown in green represent heterozygous genotypes. The ideograms for chromosomes 4 and 11 are derived from the University of California, Santa Cruz Genome Bioinformatics website (www.genome.ucsc.edu). [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]
Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project, in which 5,400 exomes have been made publicly available, and our variant has not reported in this database (Exome Variant Server, NHLBI Exome Sequencing Project, Seattle, WA; http://evs.gs.washington.edu/EVS/; last accessed January 2013). The SLC25A22 p.G110R change is predicted to affect a glycine residue that is conserved from humans to zebrafish (Fig 3). Mutating the glycine at position 110 is predicted to have a damaging effect using SIFT prediction software.

We screened with Sanger sequencing all exons and exon–intron junctions of SLC25A22 in 2 siblings from another consanguineous pedigree with MPSI from Saudi Arabia that did not have evidence of linkage in the same regions as for EP-201 and EP-202 (linkage data not shown). We also screened 2 affected siblings from a nonconsanguineous family from New Zealand, 1 of 2 affected siblings from a nonconsanguineous family from Sweden, 12 sporadic cases of MPSI from Australia, and 2 sporadic cases from the United States. We screened by examining exome sequencing data an additional 4 cases from Australia, 3 cases from the UK, and 2 cases from the US. We did not find additional cases with a mutation in SLC25A22.

Localization of WT and Mutant SLC25A22 in Cell Culture

Overexpression of GFP-tagged WT SLC25A22 resulted in a punctate pattern of protein, consistent with mitochondrial localization evident by costaining with a mitochondrial marker, as well as some widespread signal throughout the cytoplasm (Fig 4A). Overexpression of GFP-tagged mutant SLC25A22 containing the c.G328C variant resulted in a similar punctate pattern with a similar distribution. These data suggest that the mutation does not substantially alter the subcellular localization of the SLC25A22 protein.

Functional Analysis of the SLC25A22 G110R Mutant

The conservation of the altered glycine residue across species suggests that its mutation might disrupt function of the protein. To assess the pathogenic potential of the c.G328C mutation, WT and G110R mutant SLC25A22 were overexpressed in E. coli, purified, and reconstituted into phospholipid vesicles (liposomes). The WT protein efficiently catalyzed glutamate/glutamate exchange (see Fig 4B). In contrast, despite normal insertion of the mutant protein in the liposomal membrane, negligible transport activity was detected with the G110R mutant even after a long period of incubation (60 minutes). The percentage of [14C]glutamate transported by the G110R mutant GC1 into liposomes was 5.6 ± 1.1 and 2.2 ± 0.3 as compared to that transported by WT SLC25A22 after 1 and 60 minutes of incubation, respectively, in 4 experiments. These findings are analogous to what has been shown to be the case with 2 previously reported epilepsy-related SLC25A22 mutations.20,21

Discussion

We identified a novel homozygous variant in the gene SLC25A22 (also known as GC1), which encodes a mitochondrial glutamate carrier,14,22 in a family with 2 children with the severe epilepsy syndrome MPSI.
with a classical Mendelian genetics approach to identify regions with evidence of linkage in which there were a large number of candidate genes. We progressed from the stage of linkage analysis to gene discovery using developments in massively parallel sequencing in the age of a well-characterized human genome with excellent annotation of observed variants and conservation across species. A growing list of gene discoveries has unfolded in this fashion and through exome sequencing of trios with severe epilepsy, and we expect the landscape of severe childhood epilepsies to be heavily influenced by this accelerating pace of gene discovery.

Until now, MPSI has been considered a sporadic disorder without familial occurrence. Our observation that MPSI may recur in families has important genetic counseling implications, especially as we are now beginning to identify a genetic differential diagnosis for this disorder. Only a few cases of MPSI have had an identifiable etiology, and the testing of SLC25A22 provides a starting point for potential genetic diagnosis in future, especially in cases likely to have a recessive basis due to consanguinity. Although such early gene discoveries are not immediately available clinically, whole exome (or genome) sequencing is not far from clinical practice, particularly for patients with severe diagnoses such as intractable infantile onset epilepsy.

Although there are no prior reports of MPSI associated with mutations in SLC25A22, 2 distinct mutations in this gene have been associated with neonatal epileptic encephalopathy with suppression bursts (NEESBs) on EEG, a different form of early onset catastrophic epilepsy. Molinari and colleagues demonstrated that the mitochondrial glutamate transporter encoded by this gene is expressed in the developing human nervous system, notably in the hippocampus, cortex, and brainstem by the 15-week fetal stage. The homozygous missense mutations in SLC25A22 reported in association with NEESBs result in the amino acid substitutions p.P206L and p.G236W, both of which are known to alter the function of SLC25A22. Molinari and colleagues demonstrated that the mitochondrial glutamate transporter encoded by this gene is expressed in the developing human nervous system, notably in the hippocampus, cortex, and brainstem by the 15-week fetal stage. The homozygous missense mutations in SLC25A22 reported in association with NEESBs result in the amino acid substitutions p.P206L and p.G236W, both of which are shown to alter the function of SLC25A22.20,21 The mutation we describe in association with MPSI results in the amino acid substitution p.G110R, affecting a different but also highly conserved portion of the mitochondrial glutamate 1 carrier (Fig 5). Notably, all 3 of these mutated amino acids are highly conserved not only in the SLC25A22 (GC1) protein but also in the other important, paralogous mitochondrial glutamate transporter SLC25A18 (GC2; see Fig 3). The p.G110R residue is located in the third transmembrane helix of SLC25A22 in a highly conserved glycine-rich region that has been suggested to be involved in opening and closing the mitochondrial carriers on the cytosolic side; the incorporation of a positive charge into the hydrophobic membrane environment would be predicted to be deleterious for the function of SLC25A22. Our functional studies provide strong evidence that the G110R mutation essentially abrogates the function of the glutamate transporter. Thus, though a few genes in the regions of linkage were not fully covered by our whole exome and Sanger sequencing, and we cannot completely rule out the possibility that a synonymous variant affecting splicing was not recognized as such by the current methods of filtering variants, the SLC25A22 mutation provides an excellent explanation for MPSI in our pedigree.

Although both MPSI and NEESBs are devastating disorders with refractory seizures and profound developmental outcome, there are fundamental semiological and

FIGURE 3: (A) The chromatograms from Sanger sequencing confirmation of the homozygous c.G328C mutation are shown for EP-201 and EP-202. The unaffected siblings (EP-203 and EP-204) and parents (EP-205 and EP-206) are all heterozygous, as seen by the 2 differently colored peaks and the denotation of N. (B) Amino acid conservation of 2 cerebral mitochondrial glutamate transporters, SLC25A22 and SLC25A18 (also known as GC1 and GC2), in humans and of SLC25A22 in several other species in the region of a novel SLC25A22 mutation associated with migrating partial seizures in infancy. The amino acid corresponding to the location of the p.G110R mutation is in bold. [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]
electrophysiological differences that distinguish the 2 epilepsy syndromes, including age range of onset, seizure types, and EEG signature (see Fig 5). Specifically, comparing the cases of SLC25A22-associated MPSI and NEESBs, they share corpus callosum hypoplasia, but we do not observe the cerebellar hypoplasia observed in the NEESBs cases in our MPSI cases. This is, of course, not the first time a gene initially reported to be associated with a well-defined epilepsy syndrome is eventually found to be associated with new and distinct forms of epilepsy. The classic example, mentioned above, is that of SCN1A associated with both Dravet syndrome and

![Diagram of SLC25A22-associated MPSI and NEESBs](image)

FIGURE 5: The chief clinical features of migrating partial seizures in infancy (MPSI) and neonatal epileptic encephalopathy with suppression bursts (NEESBs) are shown. A schematic representation of the SLC25A22 glutamate transporter protein, with a single reported protein domain, is shown with the MPSI-associated p.G110R mutation and the 2 NEESBs-associated mutations, p.P206L and p.G236W, indicated with arrows. EEG = electroencephalogram. [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]
genetic epilepsy with febrile seizures plus, and recently with MPSI. Mutations in STXBP1 were described first as a cause of Ohtahara syndrome and have since been demonstrated to result in West syndrome and other early onset epileptic encephalopathies. Another example is that of TBC1D24, a gene initially associated both with focal epilepsy and intellectual disability and with familial infantile myoclonic epilepsy. The precise phenotypic specificity used to identify families and cases with well-defined clinical syndromes is critical to initial gene discovery. That said, given the clinical heterogeneity already observed with mutations in TBC1D24 and other epilepsy genes, we must be able to place each individual observation in a broader context when appropriate. We would predict that mutations in SLC25A22 cause severe phenotypes, but as large cohorts of patients with epileptic encephalopathies and other epilepsy syndromes are sequenced in the coming years, we will be able to better delineate the extent of the gene’s phenotypic spectrum. Ultimately, the identification of the full range of phenotypes associated with SLC25A22 and other epilepsy genes may guide further studies of the precise role of this mitochondrial glutamate transporter in epileptogenesis and provide potential avenues of targeted treatment for epileptic encephalopathy more generally.

In summary, we have shown that MPSI can be inherited with an autosomal recessive pattern. Demonstrating the strength of a combined approach coupling linkage analysis in a single pedigree with MPSI with whole exome sequencing and a targeted analysis approach in the era of a well-annotated genome, we identified a novel homozygous mutation in the mitochondrial glutamate transporter SLC25A22. Multiple lines of evidence suggest strongly that SLC25A22 is the gene responsible for MPSI in our pedigree: (1) the high probability of linkage to our candidate loci (reflected by a maximal LOD score of 2.06 for the family), (2) the presence of the homozygous variant in SLC25A22 as the only homozygous novel variant in a gene in these loci that confers an amino acid change predicted to be damaging and that is not present in control individuals, (3) the association of other SLC25A22 mutations with a distinct but also severe infantile epileptic encephalopathy, and (4) functional evidence that the G110R mutation disrupts the normal function of the SLC25A22 protein. Additional evidence would be the presence of the same homozygous mutation in an additional pedigree, but given the rarity and heterogeneity of MPSI, such evidence may be unattainable for some time.

Our finding represents 1 of the early gene identifications for a neurological disease through the combination of traditional Mendelian genetics and massively parallel sequencing. As only 1 of the families and cases we studied had MPSI associated with SLC25A22, our work illustrates the etiological heterogeneity of this devastating disease. Furthermore, we have broadened the phenotype of malignant early onset epilepsies associated with SLC25A22. Future studies on additional cohorts of patients with early onset epileptic encephalopathies will be required to determine the full phenotypic range associated with this gene.

Acknowledgment
A.P. was supported by the NIH NINDS (K23NS069784). A.J.B. was supported by the NIH NINDS (R37 NS35129). Additional funding was provided by the Comitato Telethon Fondazione Onlus No. GGP11139 and the Italian Human ProteomeNet No. RBRN07BMCT_009 (E.P.). The Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia funded this research through the Research Group Project No. 301 (M.A.S.). C.A.W. is an Investigator of the Howard Hughes Medical Institute and was also supported by the NIH NINDS (R01NS035129, R01NS035129S). NIH National Institute of Mental Health (NIMH1RC2MH089952), Manton Center for Orphan Disease Research, Dubai Harvard Foundation for Medical Research, Simons Foundation, and Nancy Lurie Marks Family Foundation. Additional funding was provided by Bryan Alzheimer’s Disease Research Center (NIA P30 AG028377).

We thank the families of the children with MPSI who participated in this research study; the following colleagues for supplying control samples: J. Burke, L. Cirulli, V. Dixon, J. Hoover-Fong, C. Hulette, D. Lancet, K. Linney, W. Lowe, P. Lugar, D. Marchuk, J. McEvoy, J. Milner, A. Need, S. Palmer, K. Pelak, E. Pras, E. Ruzzo, V. Sashi, N. Sobrierà, D. Valle, and K. Welsh-Bohmer; and Drs C. Schubert and D. Goldstein for helpful discussions that shaped the project.

DNA panels from the NINDS Human Genetics Resource Center DNA and Cell Line Repository (http://ccr.coriell.org/ninds) were used in this study. The submitters who contributed samples are acknowledged in detailed descriptions of each panel: NDPT019, NDPT022, NDPT023, NDPT024, NDPT079, and NDPT084.

Potential Conflicts of Interest
I.E.S.: board membership, UCB, Janssen-Cilag, Annals of Neurology, Epileptic Disorders; speaking fees, UCB, Janssen-Cilag, Athena Diagnostics, Eli Lilly; paid
educational presentations, Athena Diagnostics; travel expenses, Athena Diagnostics, UCB, Janssen-Cilag. A.J.B.: grants/grants pending, NIH NINDS.

References


